U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Dec 16 12:23:00 GMT 2023
Edited
by admin
on Sat Dec 16 12:23:00 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
7J9Y28299R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
Common Name English
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
Common Name English
CD340
Common Name English
NEU
Common Name English
METASTATIC LYMPH NODE GENE 19 PROTEIN
Common Name English
NGL
Common Name English
TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2
Common Name English
PROTO-ONCOGENE NEU
Common Name English
HER2/NEU
Common Name English
ERBB2
Common Name English
P185ERBB2
Common Name English
HER-2
Common Name English
HER2
Common Name English
PROTO-ONCOGENE C-ERBB-2
Common Name English
MLN19
Common Name English
ERBB-2
Common Name English
Code System Code Type Description
FDA UNII
7J9Y28299R
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
WIKIPEDIA
HER2/neu
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
UNIPROT
P04626
Created by admin on Sat Dec 16 12:23:02 GMT 2023 , Edited by admin on Sat Dec 16 12:23:02 GMT 2023
PRIMARY
From To
1_4 1_31
1_140 1_170
1_173 1_182
1_177 1_190
1_198 1_205
1_202 1_213
1_214 1_222
1_218 1_230
1_233 1_242
1_246 1_273
1_277 1_289
1_293 1_309
1_312 1_316
1_320 1_345
1_453 1_482
1_489 1_498
1_493 1_506
1_509 1_518
1_522 1_538
1_541 1_554
1_545 1_562
1_565 1_574
1_578 1_601
1_604 1_612
1_608 1_620
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_46
N 1_102
N 1_165
N 1_237
N 1_508
N 1_549
N 1_607
Related Record Type Details
WEAK INHIBITOR->TARGET
IC50
WEAK INHIBITOR->TARGET
IC50
ANTIGEN->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.
INHIBITOR -> TARGET
LIGAND->TARGET
CONJUGATED TOXIN->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
RADIOLIGAND->TARGET
LIGAND->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
CONJUGATED TOXIN->TARGET
MRG002 potently inhibited proliferation of HER2 expressing cancer cells in vitro with IC50 ranged from 1.8±0.8 to 59.9±8.9 ng/mL,
INHIBITOR -> TARGET
INHIBITOR -> TARGET
IC50
WEAK INHIBITOR->TARGET
IC50
INHIBITOR -> TARGET
INHIBITOR -> TARGET
VACCINE ANTIGEN->TARGET
INHIBITOR -> TARGET
IC50
INHIBITOR -> TARGET
CONJUGATED TOXIN->TARGET
INHIBITOR -> TARGET
CYTOTOXIC T-CELL->TARGET
INHIBITOR -> TARGET
LIGAND->TARGET
TARGET->VACCINE ANTIGEN
LIGAND->TARGET
INHIBITOR -> TARGET
IC50
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
INHIBITOR -> TARGET
HER dimerization inhibitor
BINDING
ANTIGEN->TARGET
Identified as a definitive diagnostic marker, key driver and therapeutic target for chordoma, a malignant tumor that arises from remnant notochordal cells lodged in the vertebrae
INHIBITOR -> TARGET
CONJUGATED TOXIN->TARGET
INHIBITOR -> TARGET
LIGAND->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
INHIBITOR -> TARGET
RADIOLIGAND->TARGET
INHIBITOR -> TARGET
CONJUGATED TOXIN->TARGET
ANTIGEN->TARGET
INHIBITOR -> TARGET
CONJUGATED TOXIN->TARGET
INHIBITOR -> TARGET
RADIOLIGAND->TARGET
INHIBITOR -> TARGET
BMS-690514 metabolite M2 showed HER2 inhibition similar to that of BMS-690514.
IC50
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR->OFF-TARGET
IC50
INHIBITOR -> TARGET
SELECTIVE
Ki
INHIBITOR -> TARGET
INHIBITOR -> TARGET
VACCINE ANTIGEN->TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL